NCT00641043View on ClinicalTrials.gov

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

PHASE3CompletedINTERVENTIONAL
Enrollment

389

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

June 30, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

placebo + pioglitazone (30 mg)

placebo + overcapsulated 30 mg tablet, once daily

DRUG

Linagliptin + pioglitazone (30 mg)

5 mg tablet + overcapsulated 30 mg tablet, once daily

Trial Locations (43)

Unknown

1218.15.43004 Boehringer Ingelheim Investigational Site, Feldkirch

1218.15.43001 Boehringer Ingelheim Investigational Site, Graz

1218.15.43003 Boehringer Ingelheim Investigational Site, Vienna

1218.15.43005 Boehringer Ingelheim Investigational Site, Vienna

1218.15.30004 Boehringer Ingelheim Investigational Site, Athens

1218.15.30007 Boehringer Ingelheim Investigational Site, Athens

1218.15.30017 Boehringer Ingelheim Investigational Site, Ioannina

1218.15.30002 Boehringer Ingelheim Investigational Site, Melissia-Athens

1218.15.30003 Boehringer Ingelheim Investigational Site, Nikaia

1218.15.30006 Boehringer Ingelheim Investigational Site, Thessaloniki

1218.15.30014 Boehringer Ingelheim Investigational Site, Thessaloniki

1218.15.30016 Boehringer Ingelheim Investigational Site, Thessaloniki

1218.15.36003 Boehringer Ingelheim Investigational Site, Budapest

1218.15.36004 Boehringer Ingelheim Investigational Site, Budapest

1218.15.36006 Boehringer Ingelheim Investigational Site, Budapest

1218.15.36008 Boehringer Ingelheim Investigational Site, Debrecen

1218.15.36005 Boehringer Ingelheim Investigational Site, Győr

1218.15.36002 Boehringer Ingelheim Investigational Site, Szombathely

1218.15.81001 Boehringer Ingelheim Investigational Site, Amagasaki, Hyogo

1218.15.81005 Boehringer Ingelheim Investigational Site, Koganei, Tokyo

1218.15.81002 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1218.15.81004 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo

1218.15.81003 Boehringer Ingelheim Investigational Site, Suita, Osaka,

1218.15.35007 Boehringer Ingelheim Investigational Site, Aveiro

1218.15.35001 Boehringer Ingelheim Investigational Site, Lisbon

1218.15.40504 Boehringer Ingelheim Investigational Site, Alba Iulia

1218.15.40501 Boehringer Ingelheim Investigational Site, Bucharest

1218.15.40502 Boehringer Ingelheim Investigational Site, Bucharest

1218.15.40503 Boehringer Ingelheim Investigational Site, Sibiu

1218.15.40505 Boehringer Ingelheim Investigational Site, Târgu Mureş

1218.15.34002 Boehringer Ingelheim Investigational Site, Badalona

1218.15.34011 Boehringer Ingelheim Investigational Site, Badia Del Vallés

1218.15.34001 Boehringer Ingelheim Investigational Site, Bercelona

1218.15.34012 Boehringer Ingelheim Investigational Site, Borges Del Camp

1218.15.34013 Boehringer Ingelheim Investigational Site, Centelles

1218.15.34007 Boehringer Ingelheim Investigational Site, Granada

1218.15.34008 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona)

1218.15.34009 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona)

1218.15.34004 Boehringer Ingelheim Investigational Site, Madrid

1218.15.34006 Boehringer Ingelheim Investigational Site, Madrid

1218.15.34010 Boehringer Ingelheim Investigational Site, Sant Adrià Del Besós (Barcelona)

1218.15.34005 Boehringer Ingelheim Investigational Site, Seville

1218.15.34014 Boehringer Ingelheim Investigational Site, Vic (Barcelona)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00641043 - Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone | Biotech Hunter | Biotech Hunter